published meta-analysis   sensitivity analysis   studies

mRNA vaccine (any) - second boost in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias confirmed COVID (any severity)detailed resultsCohen, 2022 0.56 [0.50; 0.63] Regev-Yochay (Comirnaty), 2022 0.70 [0.45; 1.09] Regev-Yochay (Spikevax), 2022 0.89 [0.56; 1.43] 0.65[0.50; 0.86]Cohen, 2022, Regev-Yochay (Comirnaty), 2022, Regev-Yochay (Spikevax), 2022353%30,124NAnot evaluable symptomatic Covid-19detailed resultsRegev-Yochay (Comirnaty), 2022 0.57 [0.34; 0.94] Regev-Yochay (Spikevax), 2022 0.69 [0.40; 1.19] 0.62[0.43; 0.90]Regev-Yochay (Comirnaty), 2022, Regev-Yochay (Spikevax), 202220%513NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-06-20 17:09 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 1341,1342,1343 - roots T: 290